Efficacy of weekly transtuzumab and paclitaxel in the treatment of women with HER-2/neu overexpressing metastatic breast cancer. The impact of taxane free interval on treatment outcomes
2002
Abstract
Transtuzumab, paclitaxel, metastatic breast cancer